Abstract 2085
Background
Donor lymphocyte infusions (DLI) become one of the currently used approaches to treat post-transplant relapses. However, the wide use of the different DLI strategies, its effectivity and toxicity are still unpredictable in many patients. We evaluated the impact of DLI for patients with myeloid neoplasms experienced relapse post hematopoietic stem cell transplantation (HSCT).
Methods
This study included patients with myeloid neoplasms who received DLI post HSCT at the BMT unit, Children Cancer Hospital Egypt (CCHE-57357) from 2009 to 2017. DLI was given for patients with either rising minimal residual disease (MRD) or after systemic chemotherapy for those who experienced frank relapse.
Results
A total of 20 patients received post HSCT DLI were analyzed, with median age of 7 years. About 12 patients (60%) had acute myeloid leukemia (AML), 5 with chronic myeloid leukemia (CML) and 3 cases had myelodysplastic syndrome (MDS). Seven patients had frank relapse and given systemic chemotherapy followed by DLI upon complete remission, while 13 patients received only DLI due to rising MRD. Early relapse (during 1st year) was reported in 14 cases (70%) and 7 patients relapsed beyond 1st year post-transplant. Regarding the graft status at relapse, 15 patients had maintained complete chimera while 5 patients showed mixed chimera. The one-year disease free survival (DFS) and overall survival (OS) post DLI for the whole cohort were 54% and 64%, respectively with one patient had a non-relapse mortality and 6 patients developed graft versus host disease (GvHD) post DLI. According the initial diagnosis, DFS at one year was 80% for CML, 66% for MDS and 41% for AML patients. Also DFS was better for those with late relapse (70% vs 57% for early relapse) and for those who developed GvHD post DLI.
Conclusions
DLI was associated with a durable efficacy and low toxicity in pediatric patients with hematologic malignancies. However, larger studies and standardized approaches are required to identify the outcome predictors of this treatment modality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract